US Edition
ASCO25: Roche’s Itovebi combo reduces risk of death in breast cancer by 33%
Summary by Clinical Trials Arena
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
ASCO25: Roche’s Itovebi combo reduces risk of death in breast cancer by 33%
The new OS results came from the Phase III INAVO120 study evaluating an Itovebi triple combination therapy.The post ASCO25: Roche’s Itovebi combo reduces risk of death in breast cancer by 33% appeared first on Clinical Trials Arena.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
